Synuca Therapeutics combines decades of groundbreaking research in P-type ATPases and neuroscience from Aarhus University to propose a novel disease-modifying treatment for patients suffering from Parkinson's Disease and associated disorders.
By targeting the SERCA calcium transporter, our first-in-class small molecules salvage the root disease cause by repairing the neuronal calcium imbalances caused by pathological α-Synuclein brain species.
Company Details
- Employees
- 2
- Founded
- 2025
- Address
- Aarhus, Dk
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://www.synuca.com
- HQ
- Aarhus
Synuca Therapeutics Questions
Synuca Therapeutics's website is http://www.synuca.com
Synuca Therapeutics's LinkedIn profile is https://dk.linkedin.com/company/synuca-therapeutics
Synuca Therapeutics has
2 employees.
View email and phone details for 2
employees at Synuca Therapeutics.
Synuca Therapeutics's industry is
Biotechnology Research
Synuca Therapeutics's top competitors are
Proxi Biotech,
Gefjon Pharma,
Bioinnovation Institute,
Xterna,
Yngvi Bio,
3sonic,
Beech Biotech Sa,
Microminer,
Incipiam Pharma,
Akasi Pharma.
Synuca Therapeutics's categories are Biotechnology Research
Synuca Therapeutics's founding year is 2025
